Aerie Pharmaceuticals Inc

NASDAQ:AERI   3:59:50 PM EDT
11.79
-0.31 (-2.56%)
Products, Regulatory

Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate Ar-15512 Ophthalmic Solution Achieved Statistical Significance Over Multiple Symptoms And Signs In Successful Phase 2B Clinical St

Published: 09/15/2021 22:05 GMT
Aerie Pharmaceuticals Inc (AERI) - Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate Ar-15512 (trpm8 Agonist) Ophthalmic Solution Achieved Statistical Significance Over Multiple Symptoms and Signs in Successful Phase 2b Clinical Study for the Treatment of Dry Eye Disease.
Aerie Pharmaceuticals - Ar-15512 (0.003%) Bid Advancing to Phase 3; No Treatment-related Serious Or Systemic Adverse Events Reported.
Aerie Pharmaceuticals - Achieved Statistically Significant Improvements on Multiple FDA-recognized Symptoms, Signs in Comet-1 Phase 2b Study.
Aerie Pharmaceuticals Inc - Both Formulations of Ar-15512 Were Safe and Well-tolerated.
Aerie Pharmaceuticals Inc - Expect to Have an End of Phase 2 Meeting With U.S. Food and Drug Administration in Q1 of 2022.